Lenacapavir: A Breakthrough in HIV Prevention With Just Two Annual Doses

Written by Zayra Otero,

Category: Digital Health & Omnichannel

HIV prevention has advanced significantly over the past two decades—from daily oral PrEP to bi-monthly injectable options. Now, Lenacapavir, a long-acting capsid inhibitor developed by Gilead Sciences, is poised to transform the landscape by offering a twice-yearly injection for pre-exposure prophylaxis (PrEP).

HIV prevention has advanced significantly over the past two decades—from daily oral PrEP to bi-monthly injectable options. Now, Lenacapavir, a long-acting capsid inhibitor developed by Gilead Sciences, is poised to transform the landscape by offering a twice-yearly injection for pre-exposure prophylaxis (PrEP).

What Is Lenacapavir and What Makes It Different?

Lenacapavir is a first-in-class HIV-1 capsid inhibitor that targets multiple stages of the viral life cycle by binding to the viral capsid, disrupting its formation and function. Its biannual subcutaneous administration makes it a compelling option for improving adherence, one of the biggest challenges in HIV prevention.

Besides its potential in PrEP, Lenacapavir has also shown efficacy in treating patients with multidrug-resistant HIV, reinforcing its clinical versatility.

Key Clinical Trial Results

Two pivotal Phase 3 studies—PURPOSE 1 and PURPOSE 2—led by Gilead, demonstrated compelling efficacy:

  • In PURPOSE 1, involving over 2,000 cisgender women, no HIV infections occurred among participants receiving Lenacapavir.
  • In PURPOSE 2, which included cisgender men, transgender women, and nonbinary individuals, Lenacapavir showed significantly lower HIV incidence rates compared to daily oral PrEP.
These results position Lenacapavir as one of the most effective and convenient PrEP options available today.

Companies Involved in Development and Manufacturing

The development and large-scale production of Lenacapavir have engaged several global players:

  • Gilead Sciences: Principal developer and sponsor of clinical trials.
  • ScinoPharm Taiwan: Manufacturer of the active pharmaceutical ingredient (API) used in Lenacapavir formulations【1】.
  • Catalent: Partner for advanced manufacturing of long-acting injectables, including formulations for HIV prevention【2】.

Competitive Landscape: Other Long-Acting PrEP Options

As the PrEP market expands, Lenacapavir faces both direct and indirect competition:

Product

Company

Dosing Frequency

Regulatory Status

Cabotegravir (Apretude)

ViiV Healthcare

Every 2 months

Approved in US & EU

Dapivirine Vaginal Ring

International Partnership for Microbicides

Monthly

WHO prequalified (Africa)

Islatravir

Merck (MSD)

Development paused

Trials halted for safety

While all three options offer effective protection, Lenacapavir’s twice-yearly schedule may overcome many of the logistical and adherence barriers associated with more frequent dosing.

Educational Implications for Healthcare Professionals

The introduction of Lenacapavir introduces new learning needs for medical communities:

  • Understanding a new mechanism of action (capsid inhibition)
  • Broadening the target audience beyond HIV clinics to include primary care and pharmacy settings
  • Adapting training for professionals in community health, infectious disease, and LGBTQ+ care
  • Ensuring patient adherence to biannual dosing schedules

A coordinated, well-designed medical education strategy will be essential to ensure adoption and proper use.

Conclusion

Lenacapavir represents a paradigm shift in HIV prevention. Its clinical efficacy, unique mechanism, and minimal dosing requirements position it as a promising tool to enhance public health outcomes—especially in underserved and high-risk populations.

Ready to Launch a Product in Infectious Diseases?

At Xpeer, we help pharmaceutical companies build evidence-based, measurable education campaigns for healthcare professionals—tailored by country, therapeutic area, and HCP segment.

Planning a launch like Lenacapavir? Let’s explore how educational strategy can make the difference.

References

  1. Gilead Sciences. Yeztugo (lenacapavir) Receives FDA Approval as the First and Only Twice-Yearly HIV PrEP Option. Gilead.com
  2. WHO. Lenacapavir: Long-acting injectable proves effective for HIV prevention in global trials. WHO.int
  3. Springer Nature. Long-acting injectable PrEP: comparing Lenacapavir, Cabotegravir and emerging options. Link.springer.com
  4. The New Yorker. The drug that could revolutionize the fight against HIV. NewYorker.com

Note: This article is intended for informational purposes and should not replace professional medical advice. Healthcare professionals should consult relevant guidelines and clinical trial data before making treatment decisions.